v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
| Column | Value |
|---|---|
| Trial registration number | NCT04610138 |
|
Full text link
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
|
First author
Last imported at : March 30, 2022, 3 p.m. Source : ClinicalTrials.gov |
|
|
Contact
Last imported at : March 30, 2022, 3 p.m. Source : ClinicalTrials.gov |
Not reported |
|
Registration date
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-10-30 |
|
Recruitment status
Last imported at : Feb. 13, 2023, 8:44 a.m. Source : ClinicalTrials.gov |
Completed |
|
Study design
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
|
Allocation
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
|
Design
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
|
Masking
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
|
Center
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
multi-center |
|
Study aim
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
|
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: adults, aged 40 - 90 years (inclusive) acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. participant is willing and able to follow all study procedures and assessments according to the study protocol. participant is able to consume 60 ml of fluid orally twice daily. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study. |
|
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
unable or unwilling to take znag liquid solution or matching placebo as directed. hospitalized prior to baseline for covid-19 management. need for hospitalization and/or ventilatory support at baseline. the emergence of any disease during study, other than covid-19 that could better explain the participants' signs and symptoms. severe disease: respiratory distress, or requiring supplemental oxygen, or spo2 ≤ 93% on room air, or tachypnea (respiratory rate ≥ 30 breaths/min) at baseline. history or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (nyha class 3 or 4). legal incapacity or limited legal capacity. women of childbearing potential who do not agree to use either abstinence or at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of the study. pregnant or breastfeeding. participation in another clinical study with an investigational product within the prior 12 months (per resolution 251/1997). |
|
Number of arms
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
3 |
|
Funding
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Clene Nanomedicine |
|
Inclusion age min
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
40 |
|
Inclusion age max
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
90 |
|
Countries
Last imported at : March 30, 2022, 3 p.m. Source : ClinicalTrials.gov |
Brazil |
|
Type of patients
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Mild disease at enrollment |
|
Severity scale
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
1: Mild disease at enrollment |
|
Total sample size
Last imported at : Feb. 13, 2023, 8:44 a.m. Source : ClinicalTrials.gov |
296 |
|
primary outcome
Last imported at : April 27, 2022, 3 a.m. Source : ClinicalTrials.gov |
Time to substantial alleviation of COVID-19 symptoms. |
|
Notes
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
|
Arms
Last imported at : Oct. 31, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "Low dose", "treatment_id": 305, "treatment_name": "Cnm-znag", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "High dose", "treatment_id": 305, "treatment_name": "Cnm-znag", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |